InflaRx NV Stock (IFRX): Favorable Izicopan Data Released

InflaRx NV (IFRX), a clinical-stage biopharmaceutical company, released new preclinical data on its complement inhibitor izicopan, showing a favorable reactive metabolite profile in human liver microsomes. The announcement came on 05/01/2026, as noted in a StockTitan report as of 05/13/2026. Separately, a Schedule 13G filing disclosed passive investment exceeding 5% in the company.

Shares of InflaRx NV closed at $2.43, down 2.80%, on the Nasdaq, according to TradingKey as of 05/13/2026. The company also plans to report first quarter 2026 results on May 2026, providing further visibility into its pipeline progress.

As of: 05/13/2026

By the editorial team - covering US equities and markets.

InflaRx NV: Core Business Model

InflaRx NV develops innovative therapeutics targeting the complement system and other innate immune pathways for life-threatening inflammatory diseases. The company focuses on protein engineering to create first-in-class monoclonal antibodies. Its lead programs include Gohibic (vilobelimab) for COVID-19 and vasculitis, and izicopan, an oral Factor B inhibitor for kidney diseases. InflaRx trades on Nasdaq, making it accessible to US investors interested in biotech innovation.

Founded in 2014 and headquartered in Jena, Germany, InflaRx has advanced multiple assets through clinical trials. The firm leverages its proprietary C5a and C5aR technologies, validated in over 1,000 patients across indications like ANCA-associated vasculitis and severe pneumonia.

Key Revenue and Product Drivers of InflaRx NV

Izicopan drives much of the pipeline momentum, with recent data confirming low reactive metabolite formation, reducing potential liver toxicity risks. This supports advancement toward clinical stages for rare kidney conditions. Gohibic received FDA emergency use authorization in 2023 for critically ill COVID-19 patients, marking InflaRx's first commercial product and opening US market revenue streams.

Pipeline revenue potential hinges on regulatory milestones and partnerships. InflaRx reported no significant revenue in recent quarters due to its development-stage status, but commercialization of Gohibic and upcoming Q1 2026 earnings could shift dynamics. US exposure comes via Nasdaq listing and FDA interactions.

Industry Trends and Competitive Position

The complement inhibitor market is expanding, with demand for oral therapies in renal diseases. Competitors like Novartis and Alexion (AstraZeneca) lead, but InflaRx differentiates via oral Factor B targeting. Recent data bolsters its competitive edge in safety profiles.

Why InflaRx NV Matters for US Investors

Listed on Nasdaq, InflaRx NV offers US retail investors exposure to European biotech innovation with FDA-validated assets like Gohibic. Its focus on immunology aligns with growing US healthcare spending on rare diseases, potentially benefiting from Nasdaq 100 or Russell 2000 dynamics.

Bottom Line

InflaRx NV's recent izicopan data release on 05/01/2026 highlights pipeline progress amid a Schedule 13G filing. With Q1 2026 results upcoming and Nasdaq trading, the company remains relevant for US investors tracking biotech advancements. Developments will shape its trajectory in complement therapeutics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.